Back to search
FDAFDA · Food and drugs·Recall number D-0740-2021

Adenosine Injection, USP, 60mg/20mL (3 mg/mL), 20 mL single-dose vial, Rx only, Manufactured by: Teva Pharmaceuticals USA Inc. Parsippany, NJ 07054, NDC 0703-8776-01

Published August 25, 2021 · Recall initiated: July 29, 2021

Summary

FDA records drug Class II recall D-0740-2021, published August 25, 2021 and initiated July 29, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 4,249 vials; Lot: Lot #: 100022400, exp. date 04/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Product was distributed Nationwide, including Puerto Rico.
Lot
Lot #: 100022400, exp. date 04/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Adenosine Injection, USP, 60mg/20mL (3 mg/mL), 20 mL single-dose vial, Rx only, Manufactured by: Teva Pharmaceuticals USA Inc. Parsippany, NJ 07054, NDC 0703-8776-01 recalled?

Yes. FDA published recall D-0740-2021 on August 25, 2021. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter